| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2011: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2009: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
|
|---|
| Research Abstract |
Immunological balance in AD is shifted to Th2 dominant conditions, and we have been investigated various therapeutic method to correct Th2 shifted immune systems based on the skin immunomodulation systems. In addition to supplementation of exogenous immunomodulators to the skin, we have developed a skin specific dominant negative type mutant IL-4 expressing transgenic mouse. This mouse decreased inflammation in a hapteninduced experimental dermatitis at the early phase. Wild type mouse with skin graft from the transgenic mouse, also decreased inflammation and Th2 cytokine signal proteins mRNA expression in the skin lesions. This concept, production of therapeutic peptide from keratinocytes, is a potent therapeutic strategy for various systemic diseases including allergic diseases.
|
